[en] This review focuses on recent findings on the physiology of these platelet ADP and ATP receptors, their distinct downstream intracellular signaling pathways as well as on the available agonists, antagonists and inhibitors that allow their pharmacological discrimination.
Disciplines :
Biochemistry, biophysics & molecular biology
Author, co-author :
Oury, Cécile ; Katholieke Universiteit Leuven - KUL > Molecular and Cellular Medicine > CMVB
Toth-Zsamboki, Emese; Semmelweis University Budapest > Cardiovascular Research Laboratory Group
Vermylen, Jos; Katholieke Universiteit Leuven - KUL > Molecular and Cellular Medicine > CMVB
Hoylaerts, Marc F; Katholieke Universiteit Leuven - KUL > Molecular and Cellular Medicine > CMVB
Born GV. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature 1962; 194: 927-929.
Gordon J. Extracellular ATP: effects, sources and fates. Biochem J 1986; 233: 309-319.
Oxhorn BC, Cheek DJ, Buxton IL. Role of nucleotides and nucleosides in the regulation of cardiac blood flow. AACN Clin Issues 2000; 11: 241-251.
Bodin P, Burnstock G. Purinergic signaling: ATP release. Neurochem Res 2001; 26: 959-969.
Burnstock G. Purinergic nerves. Pharmacol Rev 1972; 24: 509-581.
Ravelic V, Burnstock G. Receptors for purines and pyrimidines. Pharmacol Rev 1998; 50: 413-492.
Burnstock G, Coks C, Kasakov L, Wong HK. Direct evidence for ATP release from non-adrenergic, non-cholinergic (purinergic) nerves in the guinea-pig taenia coli and bladder. Eur J Pharmacol 1978; 49: 145-149.
Abbracchio MP, Burnstock G. Purinoceptors: are there families of P2X and P2Y purinoceptors ? Pharmacol Ther 1994; 64: 445-475.
Fredholm BB, Abbracchio MP, Burnstock G, Dubyak GR, Harden TK, Jacobson KA, et al. Towards a revised nomenclature for P1 and P2 receptors. Trends in Pharmacol Sci 1997; 18: 79-82.
Khakh BS, Burnstock G, Kennedy C, King BF, North RA, Seguela P, et al. International union of pharmacology. XXIV. Current status of the nomenclature and properties of P2X receptors and their subunits. Pharmacol Rev 2001; 53: 107-118.
Harden TK, Nicholas RA, Schachter JB, Lazarowski ER, Boyer JL. In: Turner JT, Weisman GA, Fedan JS Ed, The P2 nucleotide receptors.Humana, Totowa 1998; 109-134.
Léon C, Hechler B, Vial C, Leray C, Cazenave J-P, Gachet C. The P2Y1 receptor is an ADP receptor antagonized by ATP and expressed in platelets and megakaryoblastic cells. FEBS lett 1997; 403: 26-30.
Mahaut-Smith MP, Ennion SJ, Rolf MG, Evans RJ. ADP is not an agonist at P2X1 receptors: evidence for separate receptors stimulated by ATP and ADP on human platelets. Br J Pharmacol 2000; 131: 108-115.
Gachet C. ADP receptors of platelets and their inhibition. Thromb Haemost 2001; 86: 222-232.
Cattaneo M, Gachet C, Cazenave JP, Packham MA. Adenosine diphosphate (ADP) does not induce thromboxane A2 generation in human platelets. Blood 2002; 99: 3868-3869.
Kunapuli SP. Multiple P2 receptor subtypes on platelets: a new interpretation of their function. Trends Pharmacol Sci 1998; 19: 391-394.
Hourani SMO, Hall DA. Receptors for ADP on human platelets. Trends in Pharmacol Sci 1994: 15: 103-108.
Kunapuli SP. Molecular physiology of platelet ADP receptors. Drug Develop Res 1998; 45: 135-139.
Daniel JL, Dangelmaier C, Jin J, Ashby B, Smith JB, Kunapuli SP. Molecular basis for ADP-induced platelet activation: evidence for three distinct ADP receptors on platelets. J Biol Chem 1998; 273: 2024-2029.
Jin J, Kunapuli SP. Co-activation of two different G protein-coupled receptors is essential for ADP-induced platelet aggregation. Proc Natl Acad Sci USA 1998; 95: 8070-8074.
Eckly A, Gendrault JL, Hechler B, Cazenave J-P, Gachet C. Differential involvement of the P2Y1 and P2YΤ receptors in the morphological changes of platelet aggregation. Thromb Haemost 2001; 85: 694-701.
Park HS, Hourani SM. Differential effects of adenine nucleotide analogues on shape change and aggregation induced by adnosine 5-diphosphate (ADP) in human platelets Br J Pharmacol 1999; 127: 1359-1366.
Klages B, Brandt U, Simon MI, Schultz G, Offermanns S. Activation of G12/G13 results in shape change and Rho/ Rho-kinase-mediated myosin light chain phosphorylation in mouse platelets. J Cell Biol 1999; 144: 745-754.
Paul BZ, Daniel JL, Kunapuli SP. Platelet shape change is mediated by both calcium-dependent and -independent signaling pathways. Role of p160 Rho-associated coiled-coil-containing protein kinase in platelet shape change. J Biol Chem 1999; 274: 28293-300.
Dangelmaier C, Jin J, Daniel JL, Smith JB, Kunapuli SP. The P2Y1 receptor mediates ADP-induced p38 kinase-activating factor generation in human platelets. Eur J Biochem 2000; 267: 2283-2289.
Hollopeter J, Jantzen H-M, Vincent D, Li G, England L, Ramakrishnan V, et al. Identification of the platelet ADP receptor targeted by antithrombotic drugs. Nature 2001; 409: 202-207.
Cattaneo M, Lombardi R, Zighetti ML, Gachet C, Ohlmann P, Cazenave JP. Deficiency of (33P)2MeS-ADP binding sites on platelets with secretion defect, normal granule stores and normal thromboxane A2 production: evidence that ADP potentiates platelet secretion independently of the forniation of large platelet aggregates and thromboxane A2 production. Thromb Haemost 1997; 77: 986-990.
Cattaneo M, Lecchi A, Lombardi R, Gachet C, Zighetti ML. Platelets from a patient heterozygous for the defect of P2CYC receptors for ADP have a secretion defect despite normal thromboxane A2 production and normal granule stores: further evidence that some cases of platelet primary secretion defect are heterozygous for a defect of P2CYC receptors. Arterioscl Thromb Vasc Biol 2000; 20: E101-106.
Trumel C, Payrastre B, Plantavid M, Hechler B, Vial C, Presek P, et al. A key role for adenosine diphosphate in the irreversible platelet aggregation induced by the PAR1-activating peptide through the late activation of phosphomositide 3-kinase. Blood 1999; 94: 4156-4165.
Kim S, Foster C, Lecchi A, Quinton TM, Prosser DM, Jin J, et al. Protease-activated receptors 1 and 4 do not stimulate Gi signaling pathways in the absence of secreted ADP and cause human platelet aggregation independently of Gi signaling. Blood 2002; 99: 3629-3636.
Léon C, Vial C, Gachet C, Ohlmann P, Hechler B, Cazenave J-P, et al. The P2Y12 receptor is normal in a patient presenting a severe deficiency of ADP-induced platelet aggregation: further evidence for a distinct P2 receptor responsible for adenylyl cyclase inhibition. Thromb Haemost 1999; 81: 775-781.
Fabre JE, Nguyen M, Latour A, Keifer JA, Audoly LP, Coffman TM, et al. Decreased platelet aggregation, increased bleeding time and resistance to thromboembolism in P2Y1-deficient mice. Nat Med 1999; 5: 1199-1202.
Léon C, Hechler B, Freund M, Eckly A, Vial C, Ohlmann P, et al. Defective platelet aggregation and increased resistance to thrombosis in purinergic P2Y1 receptor-null mice. J Clin Invest 1999; 104: 1731-1737.
Nieswandt B, Schulte V, Zywietz A, Gratacap MP, Offermans S. Costimulation of Gi- and G12/G13 signaling pathways induces integrin απbβ 3 activation in platelets. J Biol Chem 2002; 277: 39493-39498.
Kauffenstein G, Bergmeier W, Eckly A, Ohlmann P, Léon C, Cazenave J-P, et al. The P2Y12 receptor induces platelet aggregation through weak activation of the απbβ3 integrin-a phosphoinositide 3-kinase-dependent mechanism. FEBS lett 2001; 505: 281-290.
Woulfe D, Jiang H, Mortensen R, Yang J, Brass LF. Activation of Rap1B by Gi family members in platelets. J Biol Chem 2002; 277: 23382-23390.
Larson MK, Chen H, Kahn ML, Taylor AM, Fabre JE, Mortensen RM, et al. Identification of P2Y12-dependent and -independent mechanisms of glycoprotein VI-mediated Rap1 activation in platelets. Blood 2003; 101: 1409-1415.
Dangelmaier C, Jin J, Smith JB, Kunapuli SP. Potentiation of thromboxane A2-induced platelet secretion by Gi signaling through the phosphoinositide-3 kinase pathway. Thromb Haemost 2001; 85: 341-348.
Kim S, Jin J, Kunapuli SP. Akt activation in platelets depends on Gi signaling pathways. J Biol Chem 2004; 279: 4186-95.
Hourani SMO. Pharmacology of the platelet ADP receptors: agonists and antagonists. Haematologica 2000; 85: 58-65.
Nurden P, Savi P, Heilmann E, Bihour C, Herbert J-M, Maffrand J-P, et al. An inherited bleeding disorder linked to a defective interaction between ADP and its receptor on platelets. J Clin Invest 1995; 95: 1612-1621.
Gachet C, Cattaneo M, Ohlmann P, Hechler B, Lecchi A, Chevalier J, et al. Purinoceptors on blood platelets: further pharmacological and clinical evidence to suggest the presence of two ADP receptors. Br J Haematol 1995; 91: 434-44.
Savi P, Beauverger P, Labouret C. Role of P2Y1 purinoceptor in ADP-induced platelet activation. FEBS lett 1998; 422: 291-295.
Foster CJ, Prosser DM, Agans JM, Zhai Y, Smith MD, Lachowicz JE, et al. Molecular identification and characterization of the platelet ADP receptor targeted by thienopyridine antithrombotic drugs. J Clin Invest 2001; 107: 1591-1598.
Nurden P, Poujol C, Winckler J, Combrie R, Pousseau N, Conley PB, et al. Immunolocalization of P2Y1 and TPalpha receptors in platelets showed a major pool associated with the membranes of alpha-granules and the open canalicular system. Blood 2003; 101: 1400-1408.
Baurand A, Eckly A, Bari N, Leon C, Hechler B, Cazenave JP, Gachet C. Desensitization of the platelet aggregation response to ADP: differential down-regulation of the P2Y1 and P2cyc receptors. Thromb Haemost 2000; 84: 484-91.
Webb TE, Simon J, Krishek BJ, Bateson AN, Smart TG, King BF, et al. Cloning and functional expression of a brain G-protein-coupled ATP receptor. FEBS Lett 1993; 324: 219-225.
King BF, Burnstock G, Boyer JL, Boeynaems J-M, Weisman GA, Kennedy C, et al. In: IUPHAR Compendium of receptor characterization and classification, 2nd ed. P2Y receptors 2001; 306-320.
Communi D, Gonzalez NS, Detheux M, Brezillon S, Lannoy V, Parmentier M, et al. Identification of a novel human ADP receptor coupled to Gi. J Biol Chem 2001; 276: 41479-41485.
Léon C, Freund M, Ravanat C, Baurand A, Cazenave JP, Gachet C. Key role of the P2Y1 receptor in tissue factor-induced thrombin-dependent acute thromboembolism: studies in P2Y1-knockout mice and mice treated with a P2Y1 antagonist. Circulation 2001; 103: 718-723.
Boyer JL, Adams M, Ravi RG, Jacobson KA, Harden TK. 2-Chloro-N6-methyl-(N)-methanocarba-2'-deoxyadenosine-3', 5'-biphosphate is a selective high affinity P2Y1 receptor antagonist. Br J Pharmacol 2002; 135: 2004-2010.
Waldo GL, Corbitt J, Boyer JL, Ravi G, Kim HS, Ji XD, et al. Quantitation of the P2Y1 receptor with a high affinity radiolabelled antagonist. Mol Pharmacol 2002; 62: 1249-1257.
Boyer JL, Romero-Avila T, Schachter JB, Harden TK. Identification of competitive antagonists of the P2Y1 receptor. Mol Pharmacol 1996; 50: 1323-1329.
Bultmann R, Tuluc F, Starke K. On the suitability of adenosine 3'-phosphate 5'-phosphosulfate as a selective P2Y receptor antagonist in intact tissue. Eur J Pharmacol 1998; 351: 209-215.
Toth-Zsamboki E, Oury C, Tytgat J, Vermylen J, Hoylaerts MF. The P2Y1 receptor antagonist adenosine-2'-phosphate-5'-phosphate non-selectively antagonizes the platelet P2X1 ion channel. Thromb Haemost 2001; 86: 1338-1339.
Boyer JL, Mohanram A, Camaioni E, Jacobson KA, Harden TK. Competitive and selective antagonism of P2Y1 receptors by N6⋯thyl 2'-deoxyadenosine 3', 5'-biphosphate. Br J Pharmacol 1998; 124: 1-3.
Baurand A, Gachet C. The P2Y1 Receptor as a Target for New Antithrombotic Drugs: A Review of the P2Y1 Antagonist MRS-2179. Cardiovasc Drug Rev 2003; 21: 67-76.
Baurand A, Raboisson P, Freund M, Lo̧n C, Cazenave J-P, Bourguignon JJ, Gachet C. Inhibition of platelet function by administration of MRS2179, a P2Y1 receptor antagonist. Eur J Pharmacol 2001; 412: 213-221.
Lenain N, Freund M, Leon C, Cazenave JP, Gachet C. Inhibition of localized thrombosis in P2Y1-deficient mice and rodents treated with MRS2179, a P2YI receptor antagonist. J Thromb Haemost 2003; 1: 1144-9.
Brown SG, King BF, Kim YC, Jang SY, Burnstock G, Jacobson KA. Activity of novel adenine nucleotide derivatives as agonists and antagonists at recombinant rat P2X receptors. Drug Dev Res 2000; 49: 253-259.
Ayyanathan K, Webb TE, Sandhu AK, Athwal RS, Barnard EA, Kunapuli SP. Cloning and chromosomal localization of the human P2Y1 purinoceptor. Biochem Biophys Res Comm 1996; 22: 419-424.
Zhang FL, Luo L, Gustafson E, Lachowicz J, Smith M, Qiao X, et al. ADP is the cognate ligand for the orphan G-protein coupled receptor SP1999. J Biol Chem 2001; 276: 8608-8615.
Ayyanathan K, Naylor SL, Kunapuli SP. Structural characterization and fine chromosomal mapping of the human P2Y1 purinergic receptor gene. Som Cell Mol Genet 1996; 22: 419-424.
Kam PC, Nethery CM. The thienopyridines derivatives (platelet adenosine diphosphate receptor antagonists), pharmacology and clinical developments. Anaesthesia 2003; 58: 28-35.
Seyfarth HJ, Koksh M, Roethig G, Rother T, Neugebauer A, Klein N, et al. Effect of 300- and 450-mg clopidogrel loading doses on membrane and soluble P-selectin in patients undergoing coronary stent implantation. Am Heart J 2002; 143: 118-123.
Herbert J-M, Frehel D, Bernat A, Badorc A, Savi P, Delebassée D, et al. Clopidogrel hydrogenosulfate. Drug Future 1993; 18: 107-112.
Geiger J, Brich J, Honig-Liedl P, Eigenthaler M, Schanzenbacher P, Herbert J-M, et al. Specific impairment of human platelet P2YAC ADP receptor-mediated signaling by the antiplatelet drug clopidogrel. Arterioscl Thromb Vasc Biol 1999; 19: 2007-2011.
Savi P, Labouret C, Delesque N, Guette F, Lupker J, Herbert JM. P2Y12, a new platelet ADP receptor, target of clopidogrel. Biochem Biophys Res Comm 2001; 283: 379-383.
Savi P, Laplace MC, Maffrand JP, Herbert J-M. Binding of [3H]-2-methylthio ADP to rat platelets: effect of clopidogrel and ticlopidine. J Pharmacol Exp Ther 1994; 269: 772-777.
Savi P, Herbert J-M, Pflieger AM, Dol F, Delebassé D, Combalbert J, et al. Importance of hepatic metabolism in the antiaggregating activity of the thienopyridine clopidogrel. Biochem. Pharmacol 1992; 44: 527-532.
Savi P, Combalbert J, Gaich C, Rouchon MC, Maffrand JP, Berger Y, et al. The antiaggregating activity of clopidogrel is due to a metabolic activation by hepatic cytochrome P450-1A. Thromb Haemost 1994; 72: 313-317.
Savi P, Pereillo JM, Uzabiaga. MF, Combalbert J, Picard C, Maffrand JP, et al. Identification and biological activity of the active metabolite of clopidogrel. Thromb Haemost 2000; 84: 891-6.
Pereillo J-M, Maftouh M, Andrieu A, Uzabiaga M-F, Fedeli O, Savi P, et al. Structure and stereochemistry of the active metabolite of clopidogrel. Drug Metabolism Disposition 2002; 30: 1288-1295.
Bennett JS. Novel platelet inhibitors. Annu Rev Med 2001; 52: 161-184.
Sugidachi A, Asai F, Ogawa T, Inoue T, Koike H. The in vivo pharmacological profile of CS-747, a novel antiplatelet agent with platelet ADP receptor antagonist properties. Br J Pharmacol 2000; 129: 1439-1446.
Sugidachi A, Asai F, Yoneda K, Iwamura R, Ogawa T, Otsuguro K, et al. Antiplatelet action of R-99224, an active metabolite of a novel thienopyridine-type G(i)-linked P2T antagonist, CS-747. Br J Pharmacol 2001; 132: 47-54.
Rao AK, Kowalska MA. ADP-induced platelet shape change and mobilization of cytoplasmic ionized calcium are mediated by distinct binding sites on platelets: 5'-p-fluorosulfonyl benzoyladenosine is a weak platelet agonist. Blood 1987; 70: 751-756.
Ding Z, Kim S, Dorsam RT, Jin J, Kunapuli SP. Inactivation of the human P2Y12 receptor by thiol reagents requires interaction with both extracellular cysteine residues, Cys17 and Cys270. Blood 2003; 101: 3908-14.
Ingall AH, Dixon J, Bailey A, Coombs ME, Cox D, McInally JI, et al. Antagonists of the platelet P2T receptor: a novel approach to antithrombotic therapy. J Med Chem 1999; 42: 213-220.
Humphries RG. Pharmacology of AR-C69931-MX and related compounds: from pharmacological tools to clinical trials. Haematologica 2000; 85: 66-72.
Huang J, Discroll EM, Gonzales ML, Park AM, Lucchesi BR. Prevention of arterial thrombosis by intravenously administered platelet P2T receptor antagonist AR-C69931MX in a canine model. J Pharmacol Exp, Ther 2000; 295: 492-499.
Wang K, Zhou X, Zhou Z, Tarakaji K, Carneiro M, Penn MS, et al. Blockade of the platelet P2Y12 receptor by AR-C69931MX sustains coronary artery recanalization and improves the myocardial tissue perfusion in a canine thrombosis model. Arterioscl Thromb Vasc Biol 2003; 23: 357-362.
Cattaneo M, Lecchi A, Randi AM, Me Gregor JL, Mannucci PM. Identification of a new congenital defect of platelet aggregation characterized by severe impairment of platelet responses to adenosine 5'-diphosphate. Blood 1992; 80: 2787-2796.
Cattaneo M, Zighetti ML, Lombardi R, Martinez C, Lecchi A, Conley PB, et al. Molecular bases of defective signal transduction in the platelet P2Y12 receptor of a patient with congenital bleeding. Proc Natl Acad Sci USA 2003; 100: 1978-1983.
Cattaneo M, Gachet C. ADP receptors and clinical bleeding disorders. Arterioscler Thromb Vasc Biol 1999; 19: 2281-5.
Leon C, Ravanat C, Freund M, Cazenave JP, Gachet C. Differential involvement of the P2Y1 and P2Y12 receptors in platelet procoagulant activity. Arterioscler Thromb Vasc Biol 2003; 23: 1941-7.
Leon C, Alex M, Klocke A, Morgenstern E, Moosbauer C, Eckly A, Spannagl M, Gachet C, Engelmann B. Platelet ADP receptors contribute to the initiation of intravascular coagulation. Blood 2004; 103: 594-600.
Buell G, Collo G, Rassendren F. P2X receptors: an emerging channel family. Eur J Neurosci 1996; 8: 2221-2228.
North RA. Molecular physiology of P2X receptors. Physiol Rev 2002; 82: 1013-1067.
Newbolt A, Stoop R, Virginio c, Surprenant A, North RA, Buell G, Rassendren F. Membrane topology of an ATP-gated ion channel (P2X receptor). J Biol Chem 1998; 273: 15177-15182.
Torres GE, Egan TM, Voigt MM. N-linked glycosilation is essential for the functional expression of the recombinant P2X2 receptor. Biochemistry 1998; 37: 4845-4851.
Kim M, Jiang LH, Wilson HL, North RA, Surprenant A. Proteomic and functional evidence for a P2X7 receptor signalling complex. EMBO J 2001; 20: 6347-6358.
Jiang LH, Kim M, Spelta V, Bo X, Surprenant A, North RA. Subunit arrangement in P2X receptors. J Neurosci 2003; 23: 8903-10.
Kim M, You OJ, Choe S. Molecular assembly of the extracellular domain of P2X2, an ATP-gated ion channel. Biochem Biophys Res Comm 1997; 240: 618-622.
Ennion S, Hagan S, Evans RJ. The role of positively charged amino acids in ATP recognition by human P2X1 receptors. J Biol Chem 2000; 275: 29361-29367.
Roberts JA, Evans RJ. ATP binding at human P2X1 receptors. Contribution of aromatic and basic amino acids revealed using mutagenesis and partial agonists. J Biol Chem 2004; 279: 9043-55.
Buell G, Lewis C, Collo G; An antagonist-insensitive P2X receptor expressed in epithelia and brain. EMBO J 1996; 15: 55-62.
Werner P, Seward EP, Buell G, North RA. Domains of P2X receptors involved in desensitization. Proc Natl Acad Sci USA 1996; 93: 15485-15490.
Rettinger J, Schmalzing G. Desensitization masks nanomolar potency of ATP for the P2X1 receptor. J Biol Chem 2004; 279: 6426-33.
King B, Chen CC, Akopian AN, Burnstock G, Wood JN. A role for calcineurin in the desensitization of the P2X3 receptor. Neuroreport 1997; 8: 1099-1102.
Dutton JL, Poronnik P, Li GH, Holding CA, Worthington RA, Vandenberg RJ, et al. P2X1 receptor membrane redistribution and downregulation visualized by using receptor-coupled green fluorescent protein chimeras. Neuropharmacology 2000; 39: 2054-2066.
Ennion SJ, Evans RJ. Agonist-stimulated internalization of the ligand-gated ion channel P2X1 in rat vas deferens. FEBS lett 2001; 489: 154-158.
Boue-Grabot E, Archambault V, Seguela P. A protein kinase C site highly conserved in P2X subunits controls the desensitization kinetics of P2X2 ATP-gated channels. J Biol Chem 2000; 275: 10190-10195.
Paukert M, Osteroth R, Geisler HS, Braerdle U, Glowatzki E, Ruppersberg JP, et al. Inflammatory mediators potentiate ATP-gated channels through the P2X3 subunit. J Biol Chem 2001; 276: 21077-21082.
Liu GJ, Brockhausen J, Bennett MR. P2X1 receptor currents after disruption of the PKC site and its surroundings by dominant negative mutations in HEK293 cells. Auton Neurosci 2003; 108: 12-6.
Toth-Zsamboki E, Oury C, Watanabe H, Nilius B, Vermylen J, Hoylaerts MF. The intracellular tyrosine residues of the ATP-gated P2X1 ion channel are essential for its function. FEBS lett 2002; 524: 15-19.
Evans RJ, Lewis C, Virginio C, Lundstrom K, Buell G, Surprenant A, et al. Ionic permeability of, and divalent cation effects on, two ATP-gated cation channels (P2X receptors) expressed in mammalian cells. J Physiol 1996; 497: 413-422.
King BF, Wildman SS, Ziganshina LE, Pintor J, Burnstock G; Effects of extracellular pH on agonism and antagonism at a recombinant P2X2 receptor. Br J Pharmacol 1997; 121: 1445-1453.
Valera S, Hussy N, Evans RJ. A new class of ligand-gated ion channel defined by P2X receptor for extracellular ATP. Nature 1994; 371: 516-519.
Valera S, Talabot F, Evans RJ. Characterization and chromosomal localization of a human P2X1 receptor from the urinary bladder. Recept Channel 1995; 3: 283-289.
Dhulipala PDK, Lianos EA, Kotlikoff MI. Regulation of human P2X1 promoter activity by beta helix-loop-helix factors in smooth muscle cells. Gene 2001; 269: 167-175.
Virginio C, Robertson G, Surprenant A, Trinitrophenyl-substituted nucleotides are potent antagonists selective for P2X1, P2X3, and heteromeric P2X2/3 receptors. Mol Pharmacol 1998; 53: 969-973.
Soto F, Lambrecht G, Nickel P, Stuhmer W, Busch AE. Antagonistic properties of the suramin analogue NF023 at heterologously expressed P2X receptors. Neuropharmacology 1999; 38: 141-149.
Klapperstuck M, Buttner C, Nickel P, Schmalzing G, Lambrecht G, Markwardt F. Antagonism by the suramin analogue NF279 on human P2X1 and P2X7 receptors. Eur J Pharmacol 2000; 387: 245-252.
Inscho EW, Cook AK, Imig JD, Vial C, Evans RJ. Physiological role for P2XI receptors in renal microvascular autoregulatory behavior. J Clin Invest 2003; 112: 1895-905.
Rettinger J, Schmalzing G, Damer S, Muller G, Nickel P, Lambrecht G. The surarnin analogue NF279 is a novel and potent antagonist selective for the P2X1 receptor. Neuropharmacology 2000; 39: 2044-53.
Hulsmann M, Nickel P, Kassack M, Schmalzing G, Lambrecht G, Markwardt F. NF449, a novel picomolar potency antagonist at human P2X1 receptors. Eur J Pharmacol 2003; 470: 1-7.
Kim YC, Brown SG, Harden TK, Boyer JL, Dubyak G, King BF, et al. Structure-activity relationships of pyridoxal phosphate derivatives as potent and selective antagonists of P2Xi receptors. J Med Chem 2001; 44: 340-349.
Evans RJ, Lewis C, Buell G, Valera S, North RA, Surprenant A. Pharmacological characterization of heterologously expressed ATP-gated cation channels (P2X purinoceptors). Mol Pharmacol 1995; 48: 178-183.
Cuzack NJ, Hourani SMO. Some pharmacological and biochemical interactions of the enantiomers of adenylyl 5′-β,γ-methylenediphosphate with the guinea-pig urinary bladder. Br J Pharmacol 1984; 82: 155-159.
Rettinger J, Schmalzing G. Activation and desensitization of the recombinant P2X1 receptor at nanornolar ATP concentrations. J Gen Physiol 2003; 121: 451-61.
Liang SX, Jenkins NA, Gilbert DJ, Copeland NG, Phillips WD. Structure and chromosome location of the mouse P2X(1) purinoceptor gene (P2rx1). Cytogenet Cell Genet 2001; 92: 333-6.
Mulryan K, Gitterman DP, Lewis CJ, Vial C, Leckie BJ, Cobb AL, Brown JE, Buell G, Pritchard CA, Evans RJ. Reduced vas deferens contraction and male infertility in mice lacking P2X1 receptors. Nature 2000; 403: 86-89.
Vial C, Evans RJ. P2X receptor expression in mouse urinary bladder and the requirement of P2X(1) receptors for functional P2X receptor responses in the mouse urinary bladder smooth muscle. Br J Pharmacol 2000; 131: 1489-95.
Vial C, Evans RJ. P2X(1) receptor-deficient mice establish the native P2X receptor and a P2Y6-like receptor in arieries. Mol Pharmacol 2002; 62: 1438-45.
Vial C, Evans RJ. Smooth muscles does not have a common P2x receptor phenotype: expression, ontogeny and function of P2x1 receptors in mouse ileum, bladder and reproductive systems. Anton Neurosci 2001; 92: 56-64.
Calvert JA, Evans RJ. Heterogeneity of P2X Receptors in Sympathetic Neurons: Contribution of Neuronal P2X1 Receptors Revealed Using Knockout Mice. Mol Pharmacol 2004; 65: 139-48.
Vial C, Hechler B, Uon C, Cazenave J-P, Gachet C. Presence of P2X1 purinoceptors in human platelets and megakaryocytic cell lines. Thromb Haemost 1997; 78: 1500-1504.
Clifford EE, Parker K, Humphreys BD, Kertesy SB, Dubyak GR. The P2X1 receptor, an adenosine triphosphate-gated cation channel, is expressed in human platelets but not in human blood leukocytes. Blood 1998; 91: 3172-3181.
Scase TJ, Heath MF, Allen JM, Sage SO, Evans RJ. identification of a P2X1 purinoceptor expressed on human platelets. Biochem Biophys Res Comm 1998; 242: 525-528.
MacKenzie AB, Mahaut-Smith MP, Sage SO. Activation of receptor-operated cation channels via P2X1 not P2T purinoceptors in human platelets. J Biol Chem 1996; 271: 2879-81.
Sage SO, MacKenzie AB, Jenner S, Mahaut-Sinith MP. Purinoceptor-evoked calcium signalling in human platelets. Prostaglandins Leukot Essent Fatty Acids 1997; 57: 435-438.
Somasundaram B, Mahaut-Smith MP. Three cation influx currents activated by purinergic receptor stimulation in rat megakaryocytes. J Physiol 1994; 480: 225-231.
Mahaut-Smith MP, Ennion SJ, Rolf MG, Evans RJ. ADP is not an agonist at P2X1 receptors: evidence for separate receptors stimulated by ATP and ADP on human platelets. Br J Pharmacol 2000; 131: 108-114.
Oury C, Toth-Zsamboki E, Thys C, Tytgat J, Vermylen J, Hoylaerts MF. The ATP-gated P2Xj ion channel acts as a positive regulator of platelet responses to collagen. Thromb Haemost 2001; 86:1264-1271.
Greco NJ, Tonon G, Chen W, Luo X, Dalal R, Jamieson GA. Novel structurally altered P(2X1) receptor is preferentially activated by adenosine diphosphate in platelets and megakaryocytic cells. Blood 2001; 98(1): 100-7.
Oury C, Toth-Zsamboki E, Vermylen J, Hoylaerts MF. Does the P(2X1del) variant lacking 17 amino acids in its extracellular domain represent a relevant functional ion channel in platelets? Blood 2002; 99: 2275-7.
Vial C, Pitt SJ, Roberts J, Rolf MG, Mahaut-Smith MP, Evans RJ. Lack of evidence for functional ADP-activated human P2X1 receptors supports a role for ATP during hemostasis and thrombosis. Blood 2003; 102:3646-51.
Mahaut-Smith MP, Sage SO, Rink TJ. Receptor-activated single channels in intact human platelets. J Biol Chem 1990; 265: 10479-10483.
Savi P, Bomia J, Salel V, Delfaud M, Herbert J-M. Characterization of P2X1 purinoreceptors on rat platelets: effect of clopidogrel. Br J Haematol 1997; 98: 880-886.
Vial C, Rolf MG, Mabaut-Smith MP, Evans RJ. A study of P2X1 receptor function in murine megakaryocytes and human platelets reveals synergy with P2X1 receptors. Br J Pharmacol 2002; 135: 363-372.
Oury C, Toth-Zsamboki E, Van Geet C, Thys C, Wei L, Nilius B, et al. A natural dominant negative P2Xj receptor due to deletion of a single amino acid residue. J Biol Chem 2000; 275: 22611-22614.
Rolf MG, Brearley CA, Mahaut-Smith MP. Platelet shape change evoked by selective activation of P2X1 purinoceptors with α,β - methylene ATP. Thromb Haemost 2001; 85: 303-8.
Rolf MG, Mahaut-Smith MP. Effects of enhanced P2X1, receptor Ca2+ influx on functional responses in human platelets. Thromb Haemost 2002; 88: 495-502.
Erhardt JA, Pillarisetti K, Toomey JR. Potentiation of platelet activation through the stimulation of P2X1 receptors. J Thromb Haemost 2003; 1: 2626-35.
Oury C, Todi-Zsamboki E, Vermylen J, Hoylaerts MF. P2X1-mediated activation of extracellular signal-regulated kinase 2 contributes to platelet secretion and aggregation induced by collagen. Blood 2002; 100: 2499-2505.
Toth-Zsamboki E, Oury C, Cornelissen H, De Vos R, Vermylen J, Hoylaerts MF. P2X1-mediatod ERK2 activation amplifies the collagen-induced platelet secretion by enhancing myosin light chain kinase activation. J Biol Chem 2003; 278: 46661-7.
Oury C, Kuijpers MJE, Toth-Zsamboki, Bonnefoy A, Danloy S, Vreys I, et at. Overexpression of the platelet P2X1 ion channel.in transgenic mice generates a novel prothrombotic phenotype. Blood 2003; 101: 3969-76.
Hechler B, Lenain N, Marchese P, Vial C, Heim V, Freund M, et al. A role of the fast ATP-gated P2X1 cation channel in thrombosis of small arteries in vivo. J Exp Med 2003; 198: 661-7.
Hechler B, Zhang Y, Eckly A, Cazenave JP, Gachet C, Ravid K. Lineage-specific overexpression of the P2Y1 receptor induces platelet hyper-reactivity in transgenic mice. J Thromb Haemost 2003; 1: 155-63.
Handa M, Gudotti G. Purification and cloning of a soluble ATP diphosphohydrolase (apyrase) from potato tubers (Solanum tuberosum). Biochem Biophys Res Comm 1996; 218: 916-923.
Fullard JF. The role of the platelet glycoprotein IIb/IIIa in thrombosis and haemostasis. Curr Pharm Des 2004; 10(14): 1567-76.
Nader HB, Lopes CC, Rocha HA, Santos EA, Dietrich CP. Heparins and heparinoids: occurrence, structure and mechanism of antithrombotic and hemorrhagic activities. Curr Pharm Des 2004; 10(9): 951-66.
Turner CH, Robling AG. Exercise as an anabolic stimulus for bone. Curr Pharm Des 2004; 10(21): 2629-41.
